Have any questions? 706-721-6582 or cts@augusta.edu
The study sponsor, Ra Pharma, is developing an investigational drug, zilucoplan, for treatment of people with gneralized myasthenia gravis, or gMG. gMG is caused when your immune system attacks part of your muscle and prevents the nerve signal from getting through. Zilucoplan is designed to prevent the immune system from attacking your muscles. The main purpose of this study is to test whether zilucoplan works and is safe for people with gMG. Participation in this study can continue until zilucoplan is approved and available in your country or until the Sponsor stops development of zilucoplan for gMG.